Wednesday, April 3, 2024
4:30 p.m. ET
Duration: 30 minutes

This webinar will provide a brief review of pathophysiology and novel therapeutic targets in MG, an introduction to the concept of induction and maintenance therapy in autoimmune neurologic conditions, a summary of the data from the Phase II clinical trial of batoclimab in MG, and an overview of the Phase III study design of batoclimab in generalized MG.